J. Del Campo

Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer

Ignace Vergote, N. Finkler, J. Del Campo et al. · European Journal of Cancer · 2009 · 102 citations

Medicine, Oncology, Pharmacology +16

A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer

Giuseppe Roberto D’Agostino, J. Del Campo, Begoña Mellado et al. · International Journal of Gynecological Cancer · 2006 · 83 citations

Medicine, Oncology, Pharmacology +16

BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study.

Tanguy Y. Seiwert, Paul M. Clément, Didier Cupissol et al. · Journal of Clinical Oncology · 2010 · 39 citations

Medicine, Oncology, Pharmacology +9

Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer

Ignace Vergote, N. Colombo, E. Kutarska et al. · Journal of Clinical Oncology · 2009 · 20 citations

Medicine, Oncology, Pharmacology +17

First line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression free survival

Gunnar B. Kristensen, Ignace Vergote, E. Eisenhauer et al. · Journal of Clinical Oncology · 2004 · 18 citations

Medicine, Gynecology, Oncology +11